Evidence map›Paper›PMID 30555636›Full record

ArticleOncotarget2018

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified

Maximilian Marhold, Erwin Tomasich, Michael Schwarz, Simon Udovica, Andreas Heinzel, Paul Mayer, Peter Horak, Paul Perco, Michael Krainer

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Maximilian MarholdDepartment for Internal Medicine I-Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Erwin TomasichDepartment for Internal Medicine I-Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Michael SchwarzClinic of Internal Medicine I, Wilhelminenspital Wien, Vienna, Austria.
Simon UdovicaClinic of Internal Medicine I, Wilhelminenspital Wien, Vienna, Austria.
Andreas HeinzelEmergentec biodevelopment, Vienna, Austria.
Paul MayerEmergentec biodevelopment, Vienna, Austria.
Peter HorakDepartment for Translational Oncology, German Cancer Research Institute (DKFZ), Heidelberg, Germany.
Paul PercoEmergentec biodevelopment, Vienna, Austria.
Michael KrainerDepartment for Internal Medicine I-Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center Vienna · ATWilhelminen Hospital · ATHeidelberg University · DEMedical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the concept of synthetic lethality, describing a cellular state where loss of two genes leads to a non-viable phenotype while loss of one gene can be compensated, has emerged as a novel strategy for cancer therapy. Various compounds targeting synthetic lethal pathways are either under clinical investigation or are already routinely used in multiple cancer entities such as breast cancer. Most of them target the well-described synthetic lethal interplay between PARP1 and BRCA1/2. In our study, we investigated, using an

Indexed as

breast cancercancerdrug combinationsynthetic lethalitytreatment

Identifiers

PMID30555636
PMCPMC6284748
OpenAlexW2901363681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.